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NonadherenceBackground: Once-daily extended-release (XR) antiepileptic drugs (AEDs) offer potential adherence and tolera-
bility advantages over their BID immediate-release (IR) counterparts. However, patients with epilepsy will inev-
itably be at least occasionally nonadherentwith a prescribed dosing regimen, regardless of formulation. Although
perturbations in plasma concentrations due to dosing irregularities may have clinical consequences for AEDs
with concentration–response relationships, clinical studies that deliberately expose patients to speciﬁc dosing
irregularities in order to assess the effect on plasma concentrations and determine appropriate corrective actions
would be unethical.
Methods: Computer simulation was used to assess the impact of irregular dosing on topiramate (TPM) concentra-
tions in noninduced (monotherapy/neutral cotherapy) and induced (adjunctive therapy with enzyme-inducing
AEDs) states using a population pharmacokinetic (PK) model developed to predict steady-state plasma
concentration–time proﬁles produced by once-daily Trokendi XR® (extended-release topiramate capsules,
Supernus Pharmaceuticals) and BID TPM-IR.
Results: Computer simulations predicted that, relative to adherent dosing, delaying a dose 4 to 24 h in noninduced
patients would decrease trough (Cmin) levels 9% to 31% in the case of TPM-IR and 6% to 27% with Trokendi XR; a
single omitted dose would reduce Cmin by 21% (TPM-IR) and 27% (Trokendi XR). After dose recovery to correct
for a delayed or omitted dose, simulated peak concentration (Cmax) was higher than steady-state Cmax, regardless
of formulation, although the magnitude of “overshoot” was consistently lower with Trokendi XR vs. TPM-IR.
Doubling of a dosewould increase Cmax by 26% and 28%, respectively. Predicted changes for nonadherent vs. adher-
ent dosing were greater in the induced vs. noninduced state but were generally comparable for the two TPM
formulations. Because the long half-life of TPM has been cited as a justiﬁcation for QD dosing of TPM-IR, simula-
tions also compared steady-state PK proﬁles of once-daily Trokendi XR and QD TPM-IR. Predicted TPM plasma
concentration–time proﬁles were markedly different, as demonstrated by peak–trough ﬂuctuation (QD TPM-IR,
64%; QD Trokendi XR, 18%) and 34% lower Cmin with QD TPM-IR.
Conclusions: Based on these simulations, dosing irregularities with once-daily Trokendi XR should pose no greater
risk than with BID TPM-IR. In the event of a delayed or omitted Trokendi XR dose, TPM concentrations can be re-
stored in noninduced and induced states by administering the delayed/omitted dose at any time during the next
dosing interval or by adding the missed dose to the next scheduled dose.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ls, Inc., 1550 East Gude Drive,
n), jwheless@uthsc.edu
niversity of Tennessee Health
, TN 38105, USA.
. This is an open access article under1. Introduction
Dosing irregularities are common problems in managing acute and
chronic diseases. A retrospective analysis of dosing irregularities in
chronic disease found that up to 42% of patients did not takemedication
as prescribed; reasons cited for nonadherence included forgetting
doses, forgetting reﬁlls, side effects, and cost [1]. In epilepsy, as many
as seven in ten patients have reported missing doses of antiepileptic
drugs (AEDs) at some time during treatment [2]. A more recent patient
survey found that 66% of patients reported omitting doses at least once athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Testing the population PKmodel: Observed vs. simulated TPMplasma concentration–
time proﬁles (neutral AED therapy). Panel A: Mean steady-state dose-normalized
(200 mg/day) concentration–time data observed in patients with epilepsy taking
Q12hr TPM-IR and QD Trokendi XR (n = 49). Panel B: Predicted steady-state concen-
tration–time proﬁle simulated for 100mg Q12hr TPM-IR and 200mg QD Trokendi XR.
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cause of nonadherence [3,4]. Although patients and physicians agreed
that efﬁcacy and safety/tolerability are the most important attributes
in AED selection, patients ranked dosing convenience as the next most
important attribute [4].
Medication adherence declines as daily dose frequency increases [5];
less frequent dosing simpliﬁes the pill-taking regimen andmay improve
adherence during chronic therapy [6,7]. A twice-daily (BID) immediate-
release (IR) therapy reformulated as a once-daily (QD) extended-
release (XR) AED that slows AED absorption can prolong the dosing in-
terval and minimize ﬂuctuations in plasma concentrations [8], which
may have positive effects on adherence, tolerability, and effectiveness.
Despite the potential advantages of XR formulations, clinicians may
be hesitant to switch patientswith epilepsy from an IR AEDdosed BID to
its XR counterpart dosed QD based on the belief that a dosing error in-
volving 100% of the total daily dosage has a greater impact on plasma
concentrations than a dosing error involving 50% of the total daily
dosage [9]. However, such a perspective does not take into account
the potential for XR AEDs to maintain therapeutic plasma concentra-
tions for longer intervals due to slowed drug input and administration
of a single large dose rather than multiple smaller doses. In contrast to
expectations, the characteristics of an XR AED can blunt the impact of
dosing errors on plasma concentrations.
Trokendi XR® (extended-release topiramate capsules, Supernus Phar-
maceuticals, Inc.) is a novel once-daily formulation of topiramate (TPM).
The speciﬁc combination of IR and XR beads using the Microtrol® drug
delivery technology slows TPM absorption from Trokendi XR more than
20-fold relative to the morning TPM-IR dose [10]. A randomized cross-
over study in volunteers comparing 200 mg of once-daily (QD) Trokendi
XR to 100mgBID TPM-IR (Topamax®, Janssen Pharmaceuticals) demon-
strated that QD Trokendi XR is bioequivalent to BID TPM-IR [11], but sig-
niﬁcantly reduces peak–trough ﬂuctuation for more constant plasma
concentrations over the dosing interval. However, this study measured
steady-state concentrations in conditions of adherent dosing.
Ethical considerations would make it difﬁcult to justify a clinical
study in which patients with epilepsy are deliberately exposed to irreg-
ularities in AED dosing. However, population pharmacokinetic (PK)
modeling and simulation is a powerful tool that can accurately predict
dosing-related changes in plasma concentration–time proﬁles. This
technique was used to compare the effects of delayed, omitted, and
doubled doses of QD Trokendi XR and BID TPM-IR. In addition, the sim-
ulated steady-state PK proﬁles of QD Trokendi XR and QD TPM-IR were
compared since the long half-life of TPM has been cited as justiﬁcation
for QD dosing of TPM-IR in some patients (e.g., receiving TPM asmono-
therapy or adjunctively with noninducing AEDs) [12].
2. Materials and methods
Population PKmodeling and simulation was performed using nonlin-
ear mixed-effects modeling (NONMEM, ICON Development Solutions;
PLTTools, P Less Than Company). A linear two-compartment PK model
with ﬁrst-order elimination from the central compartment was initially
developed. This primary structural model used TPM concentration–time
data collectedwith intensive PK sampling over a 168-hour postdose peri-
od in a single-dose, randomized sequence (fed/fasted) crossover study in
healthy adult volunteers (ages 18–55 years, N = 31). A ﬁnal population
PK model was developed using TPM plasma concentration–time data
from intensive PK sampling on three occasions in adult patients with
epilepsy (ages 19–65 years, N=62). These patientswere receiving stable
BID TPM-IRwith neutral cotherapy (i.e., monotherapy or adjunctive ther-
apy with noninducing AEDs, n = 49) or adjunctive enzyme-inducing
AEDs (EIAEDs, n=13) andwere switched to identical total daily dosages
of QD Trokendi XR. Release of AED from the dosage unit and subsequent
absorption in the gut was modeled with a ﬁrst-order rate constant and
absorption lag. Covariates incorporated into the ﬁnal model included
concomitant use of EIAEDs and body weight (see SupplementalInformation for parameter estimates used in theﬁnalmodel). Subsequent
model validation included visual inspection of model graphics for good-
ness of ﬁt and bootstrap analysis of 500 datasets obtained from the orig-
inal dataset using sampling with replacement.
The population PK model was used to simulate steady-state TPM
plasma concentration–time proﬁles resulting from different dosing sce-
narios, comparing adherent and nonadherent dosing in neutral and in-
duced states. In these simulations, typical values of model parameters
were used to produce a single concentration–time proﬁle for each
dosing scenario by setting the variance of within- and between-subject
terms to zero. The resulting proﬁle represented the central tendency
of the population data. Adherent dosing assumed administration of
200-milligram TPM-IR in equally divided doses every 12 h (100 mg
Q12hr) and administration of 200 mg Trokendi XR as a single daily
dose every 24 h (200 mg QD). Nonadherent dosing scenarios were
1) a dose administered 4, 8, 12, 16, or 24 h late, with the next dose ad-
ministered as scheduled; 2) amissed dose thatwas recovered by adding
the omitted dose to the next scheduled dose; and 3) a single doubled
dose. For the scenario of dosing 24 h late, the simulation assumed that
one dose of QD Trokendi XR (200 mg) is omitted vs. two 100-mg
doses of Q12hr TPM-IR (for a total daily dose of 200 mg) before sched-
uled dosing resumed. Predicted Cmin and/or Cmax concentrations for
each nonadherent dosing scenario were compared with predicted con-
centrations for adherent dosing; percent ﬂuctuation was calculated as:
[(Cmax,ss 0–24− Cmin,ss 0–24) / Cavg,ss 0–24] × 100%. The steady-state con-
centration–time proﬁle for QD dosing of TPM-IR was also simulated.3. Results
3.1. Simulated vs. observed TPM plasma concentration–time proﬁles
To examine the predictability of the ﬁnal population PK model, sim-
ulated concentration–time proﬁles were compared with observed
mean dose-normalized (200 mg/day) concentration–time data at
steady state from patients with epilepsy. The population PK model
closely replicated the observed data (Fig. 1).
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The predicted effects (relative to adherent dosing) of increasingly
prolonged dosing delays of a single dose are summarized in Table 1.
Simulations for Q12hr TPM-IR assumed a delay in the ﬁrst daily dose
with the second dose being administered as scheduled; modeling of
12- and 24-hour delays assumed a doubling and trebling (respectively)
of the TPM-IR dose (recovered dose plus scheduled dose). Modeling of
the 16-hour delay assumed that the two recovered doses (total,
200 mg) would be administered 4 h after the day's second dose should
have been administered. In the case of QD Trokendi XR, simulation of
24-hour dosing delay assumed simultaneous administration of recov-
ered dose and scheduled dose (total, 400mg). In these simulations, pre-
dicted changes in TPM plasma concentrations followed a pattern of
increasingly larger decrements in trough (Cmin) levels and increasingly
larger increments in peak (Cmax) concentrations as the interval between
an omitted dose and recovered dose increased.
QD Trokendi XR and Q12hr TPM-IR were not substantially different
across the range of dosing delays in terms of predicted decrements in
trough concentrations. Relative to adherent dosing, changes in Cmin con-
centrations in the neutral state ranged from −6% to −27% with QD
Trokendi XR dose delays and−9% to−31% with Q12hr TPM-IR. With
EIAEDs in the model, Cmin concentration changes ranged from−10% to
−39% (QD Trokendi XR) and−15% to−45% (Q12hr TPM-IR).
The 12-hour dosing delay was an inﬂection point for differences be-
tween QD Trokendi XR and Q12hr TPM-IR in that peak concentrations
following dose delay/recovery were substantially greater with Q12hr
TPM-IRwhen delays exceeded 12 h (Table 1, Fig. 2). Comparedwith ad-
herent dosing, thepredicted changes in Cmax ranged from+3% to+14%
with QD Trokendi XR vs. +2% to +30% with Q12hr TPM-IR in neutral
conditions and +5% to +25% (QD Trokendi XR) vs. +2% to +53%
(Q12hr TPM-IR) in the induced state. After TPM-IR or Trokendi XR
dosing resumed, simulated Cmax was higher than steady-state Cmax;
the magnitude of the “overshoot” was greater with TPM-IR than with
Trokendi XR (Fig. 2).
Overall, perturbations in TPM concentrations were substantially
greater in induced vs. neutral conditions for both QD Trokendi XR and
Q12hr TPM-IR. However, even in induced patients, predicted changes
in Cmin and Cmax associated with QD Trokendi XR dosing delays were
generally smaller than with Q12hr TPM-IR.3.3. Simulations of an omitted dose
In the simulation of an omitted dose, the interval between last ad-
ministered dose and dose recovery was 48 h for QD Trokendi XR and
24 h for Q12hr TPM-IR. Following the missed dose, the subsequent
dose recovery represented 200% of the total daily dose for Trokendi XR
and 100% for TPM-IR. Predicted changes from adherent dosing for
Cmin and Cmax are shown in Table 2; plasma concentration–time proﬁles
are depicted in Fig. 3. Despite the twofold differences in the time inter-
val and magnitude of recovered dose, formulations differed b10% inTable 1
Delayed dose/dose recovery simulations: predicted change in TPM concentrations relative to a
Delay, hr Trough (Cmin) concentration before next scheduled dose
Neutral Induced
QD Trokendi XR Q12hr TPM-IR QD Trokendi XR Q12hr TPM-
4 −6% −9% −10% −15%
8 −12% −16% −18% −26%
12 −17% −21% −25% −33%
16 −21% −25% −31% −38%
24 −27% −31% −39% −45%
Neutral = monotherapy or adjunctive therapy with noninducing AEDs.
Induced = adjunctive enzyme-inducing AEDs.terms of Cmin and Cmax changes vs. adherent dosing, regardless of met-
abolic state.
3.4. Simulations of a doubled dose
This scenario assumed that the dose intervals were correct but one
dose was doubled to 100% of the total daily dose for TPM-IR and 200%
of the total daily dose for Trokendi XR. Predicted plasma concentration–
time proﬁles are shown in Fig. 4. Increases in peak TPM concentration
(vs. adherent dosing) following a doubled dose of Trokendi XR or
TPM-IRwere comparable in both the neutral (+28% and+26%, respec-
tively) and the induced (+41% and +39%, respectively) states.
3.5. Simulations of QD dosing
Fig. 5 presents simulations estimating steady-state plasma concen-
trations when Trokendi XR and TPM-IR are both dosed once-daily; PK
parameters are summarized in Table 3. Relative to QD Trokendi XR,
QD TPM-IR was associated with a higher Cmax (+14%), lower Cmin
(−34%), and lower Cavg (−11%) in neutral conditions. As a result, ﬂuc-
tuation was 64% for QD TPM-IR vs. 18% for QD Trokendi XR.
4. Discussion
Predicted changes in TPM plasma concentrations for nonadherent vs.
adherent dosing suggest that common dosing errors with QD Trokendi
XR would likely pose no greater clinical risks than with Q12hr TPM-IR.
Predicted reductions in trough TPM concentrations with delayed QD
Trokendi XR dosing were not as pronounced as with Q12hr TPM-IR.
When simulations assumed that dosing would continue as scheduled,
peak concentrations were typically blunted with QD Trokendi XR,
resulting in less “overshoot” in Cmax when compared with Cmax for
Q12hr TPM-IR.With TPM-IR, Cmax increases of 30% (noninduced/neutral)
and N50% (induced) after dose recovery could be clinically notable. Un-
like the late-dosing simulations inwhich both formulationswere delayed
the same length of time, the omitted-dose scenario imposedmore severe
conditions onTrokendi XR in terms of TPMconcentrationﬂuctuation. The
time between dose administration and recovery was longer for Trokendi
XR (48 h vs. 24 h), while themagnitude of omitted (100% vs. 50%, respec-
tively) and subsequently restored (200% vs. 100%, respectively) doses
were greater. Nonetheless, the omitted-dose simulation showed that re-
ductions in trough levels and subsequent increases in peak levels relative
to adherent dosing were similar for QD Trokendi XR and Q12hr TPM-IR.
Similarly, in the scenario of a doubled dose, increases in peak TPM con-
centration were of comparable magnitude vs. adherent dosing for both
formulations, providing reassurance that a missed Trokendi XR dose
can be restored at any time within the dosing interval [11]. With the in-
clusion of EIAED coadministration in the simulations, comparisons be-
tween formulations showed the same trends as in the neutral state,
although plasma concentration changeswere generally of greatermagni-
tude with both formulations.dherent dosing with QD Trokendi XR and Q12hr TPM-IR.
Peak (Cmax) concentration after recovered dose
Neutral Induced
IR QD Trokendi XR Q12hr TPM-IR QD Trokendi XR Q12hr TPM-IR
+3% +2% +5% +2%
+6% +4% +10% +5%
+10% +12% +15% +17%
+12% +23% +21% +36%
+14% +30% +25% +53%
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Fig. 2. Predicted steady-state TPM plasma concentration–time proﬁles simulated for 100mg Q12hr and 200mg QD Trokendi XRwith delays of 8, 12, and 24 h (neutral cotherapy). Arrow
indicates administration of recovered doses. Simulations for Q12hr TPM-IR assumeda delay in theﬁrst daily dose and the seconddose administered as scheduled. For 12-hour and 24-hour
delays in TPM-IR dosing, modeling assumed administration of 200 mg TPM-IR (12-hour delay) and 300 mg (24-hour delay), representing recovered dose(s) plus scheduled dose. In the
case of 24-hour delay with Trokendi XR, modeling assumed administration of 400 mg (recovered dose plus scheduled dose).
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34 S.T. Brittain, J.W. Wheless / Epilepsy & Behavior 52 (2015) 31–36The simulations assumed Q12hr dosing for TPM-IR in accordance
with BID dosing recommendations in Topamax prescribing information
[13]. However, TPM has a long elimination half-life, substantially ex-
ceeding 24 h in the absence of enzyme induction [14]. Based on the pre-
mise that the dosing interval should be equal to drug half-life, a half-life
that exceeds 24 h would seem to support QD dosing of any TPM formu-
lation, at least in patients not receiving EIAEDs. However, in the simula-
tions comparing steady-state PK, 24-hour plasma concentration–time
curves were markedly different for QD Trokendi XR and QD TPM-IR.
The predicted trough TPM concentration was lower, and the peak con-
centration was higher with QD TPM-IR, resulting in much greater ﬂuc-
tuation vs. QD Trokendi XR.
Plasma concentrationﬂuctuation is a functionof available dose, dosing
interval, half-life, and absorption rate. Three of these parameters— dose,
dosing interval, half-life — were identical in the simulations comparing
QDdosing of Trokendi XR and TPM-IR. Thus, slower drug release reﬂected
by a N20-fold slower TPM absorption rate with Trokendi XR vs. TPM-IR
accounted for themarkedly diminishedﬂuctuationofQDTrokendiXR. Al-
though the analysis reported here did not simulate delayed or missed
doses if TPM-IR was dosed QD, a markedly lower Cmin vs. Trokendi XR
would be expected after any delay given that the predicted Cmin was al-
ready 34% lower with adherent QD dosing of TPM-IR.
In the case of QD Trokendi XR vs. Q12hr TPM-IR, computer simula-
tions showed that QD Trokendi XR was at least as forgiving as BID
TPM-IR, which is counter to expectations that an omitted dose of a QD
XR formulation would pose a greater clinical risk than an omitted dose
of an IR AED being dosed BID [9]. However, this perception does not
take into account the magnitude of administered dose (e.g., 100% for
QDXR formulation vs. 50% of total daily dosage for BID IR drug) and con-
trolled drug input of XR formulations such as Trokendi XR. Controlled
drug release regulates drug input, produces more constant TPM plasma
concentrations, and blunts the impact of irregularities in QD dosing.
Computer simulation is a cost-effective means of systematically
evaluating many different permutations of drug administration and hasTable 2
Omitted dose simulations: change in TPM concentrations vs. adherent dosing with QD
Trokendi XR and Q12hr TPM-IR.
Trough (Cmin) concentration
before next scheduled dose
Peak (Cmax) concentration after
recovered dose
QD Trokendi XR Q12hr TPM-IR QD Trokendi XR Q12hr TPM-IR
Neutral −27% −21% +14% +12%
Induced −39% −33% +25% +17%been used to evaluate the PK impact of irregular dosing for several
AEDs in order to determine appropriate corrective actions [15–19]. For
ease of illustration, the concentration–time proﬁles presented in our
analysis depict the “typical patient” based on the population mean for
each dosing scenario, similar to simulations comparing XR and IR formu-
lations of lamotrigine [19]. As demonstrated with extended-release
divalproex dosing [20], simulations can also incorporate estimates for
between- andwithin-patient variability. This approach generates plasma
concentration–time proﬁles that reﬂect the predicted range of Cmin and
Cmax concentrations that could occur with speciﬁc scenarios of dosing
nonadherence and dosing corrections in themajority of patients. Such in-
formation is particularly informative for AEDs, including divalproex, with
nonlinear PK, poor correlation between dose and/or plasma concentra-
tions, and relatively narrow therapeutic index. In contrast, TPM exhibits
a linear dose–concentration relationship (i.e., at doses N25 mg) and has
a relatively broad reference range [21].
Although computer simulations cannot replace real-world experi-
ence in patients, the simulations presented here are rooted in PK data
and intrinsic factors collected from patients with epilepsy in clinicalTo
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Fig. 3. Simulated steady-state TPM plasma concentration–time proﬁles following omitted
dose of 100 mg TPM-IR (50% of total daily dose) and 200 mg Trokendi XR (100% of total
daily dose). Arrows indicate administration of omitted dose and scheduled dose (total
dose: TPM-IR, 200 mg; Trokendi XR, 400 mg).
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Fig. 4. Simulated TPM plasma concentration–time proﬁles when doses of TPM-IR and
Trokendi XR were doubled at steady state. Arrow indicates administration of doubled
dose (TPM-IR, 200 mg; Trokendi XR, 400 mg) at the scheduled dosing time.
Table 3
Once-daily dosing: simulated steady-state pharmacokinetics of Trokendi XR and TPM-IR.
Simulated steady-state PK after once-daily dosing
QD Trokendi XR QD TPM-IR
AUC, hr·mg/L 149⁎ 134
Cmax, mg/L 6.6 7.7
Cmin, mg/L 5.5 4.1
Cavg, mg/L 6.2 5.6
Tmax, hr 6.0 1.0
⁎ Despite ~11% difference in TPM exposure, Trokendi XR and TPM-IR (Topamax) are
bioequivalent [13].
35S.T. Brittain, J.W. Wheless / Epilepsy & Behavior 52 (2015) 31–36studies and avoid the potential ethical issues of studies that would de-
liberately delay or withhold AED doses during treatment. In the case
of QD Trokendi XR, simulations showed that TPM concentrations can
be restored by administering the delayed/missed dose at any time dur-
ing the next dosing interval or by adding the omitted dose to the next
scheduled dose, regardless of AED cotherapy (neutral or EIAED).
5. Conclusions
Using a population PKmodel that was highly predictive of observed
steady-state TPM plasma concentrations, simulations that assumed BID
(Q12hr) dosing of TPM-IR showed that delays in QD Trokendi XRdosing
would be expected to have less effect on TPM plasma concentrations
than delays with TPM-IR dosing. After an omitted QD Trokendi XR
dose (100% of total daily dose), the predicted reduction in trough
concentration was only slightly greater than after an omitted Q12hr
TPM-IR dose (50% of total daily dose). Simulations predicted markedly
different steady-state plasma concentration–time curves if Trokendi
XR and TPM-IR were both dosed QD. In the simulation of steady-state
QD dosing, the lower Cmin concentrations predicted for QD TPM-IR sug-
gested a higher risk of seizures despite adherent QD TPM-IR dosing.
Results of simulated doubled dosing showed that TPM levels can be re-
stored by administering a delayed or omitted dose any time within the
dosing interval. Simulations showed that predicted increases in peak
TPM concentrations following doubled doses were comparable for the
two formulations. The impact of delayed, omitted, or doubled dosesTPM-IR QD
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Fig. 5. Simulated steady-state TPM concentration with QD dosing of 200 mg Trokendi XR
and 200 mg TPM-IR.was consistently greater with enzyme induction. Based on these simu-
lated dosing scenarios, dosing irregularities with once-daily Trokendi
XR should pose no greater risk than with BID TPM-IR.
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